Report Overview

The Australian Pouchitis Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Pouchitis is an inflammatory condition of the ileal pouch. It happens when the ileal pouch reservoir becomes inflamed or irritated. Pouchitis mainly occurs in a patient who has undergone ileal pouch-anal anastomosis (IPAA), a surgical procedure for removing the rectum and the large intestine. About half of the number of patients who undergo this surgery develops Pouchitis at least once in their lifetime. Every year, up to 40% of patients who undergo IPAA surgery develops Pouchitis. However, the exact cause of Pouchitis has not yet been determined. Pouchitis has been observed occurring among patients suffering from ulcerative colitis or some other form of colitis, and also rarely among patients with genetic condition (familial adenomatous polyposis), in which many polyps are formed in the colon. Other factors responsible for the development of Pouchitis include backwash ileitis, long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs), increased number of platelets, smoking, and health conditions such as diabetes or heart disease. Common symptoms of Pouchitis include tenesmus, straining during defecation, blood in stool, seepage of waste matter while asleep, incontinence, tail bone pain, abdominal cramp, and increased frequency in night-time bowel movements.



Market Drivers

The Australian Pouchitis Therapeutics market is expected to expand at a significant CAGR during the forecast period. No single therapy has been approved in the Australia for the treatment of Pouchitis. However, a few pipeline molecules are waiting for approval, such as alicaforsen, the molecule developed by Atlantic Healthcare plc. Rise in the prevalence of ulcerative colitis, increase in the number of ileal pouch-anal anastomosis procedure, long-term usage of non-steroidal anti-inflammatory drugs, and growth in the geriatric population are the key factors driving the Pouchitis Therapeutics market.

However, disappointing result of promising pipeline molecules and stringent government regulations are anticipated to hamper the growth of the Pouchitis Therapeutics market during the forecast period.